Please login to the form below

Not currently logged in
Email:
Password:

Verastem promotes Robert Forrester to CEO

Takes over from Christoph Westphal who moves to executive chairman

US biotech Verastem has announced a change in personnel at the very top, with Robert Forrester to replace Christoph Westphal as CEO on July 1, while Westphal will become executive chairman.

Forrester currently serves as president and chief operating officer at the company, which specialises in developing drugs to treat cancer by the targeted killing of cancer stem cells.

His positions prior to joining Verastem includes senior roles at life sciences firms Forma Therapeutics, CombinatoR and Coley. He has experience in other industries too, serving at investment banks BZW and UBS, and at investment group MeesPierson.

“Robert's experience and expertise are perfectly suited to advancing our company through clinical development and creating value for shareholders, making this an ideal time to effect this transition,” said Westphal, who also confirmed his own future interest in the company.

“As the largest investor, and with an active 10b5-1 buying plan, Verastem will remain my principal focus. Robert and I will continue to work closely with the board of directors to implement our strategy.”

11th June 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics